Zymeworks price target raised to $18 from $16 at Citi
The Fly

Zymeworks price target raised to $18 from $16 at Citi

Citi analyst Yigal Nochomovitz raised the firm’s price target on Zymeworks (ZYME) to $18 from $16 and keeps a Buy rating on the shares. The company’s Q3 earnings call was “very incrementally informative,” the analyst tells investors in a research note. The firm says that most notably, Zymeworks completed the first $30M tranche of the share repurchase program as of October 31, buying back 2.5M shares at an average price of $11.79.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App